Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2020-10-27 Capital/Financing Update
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 2 to a Form S-1 Registration Statement filed with the SEC, which is a registration statement for securities under the Securities Act of 1933. It includes details about the securities being registered, the company overview, risk factors, use of proceeds, and other information typical of a registration statement for an initial public offering or other securities offering. This is not an annual report, earnings release, or any other financial report type. It is a capital markets filing related to the registration of securities for sale to the public. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, confirming it is not merely an announcement but the actual registration statement amendment.
2020-10-27 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from an underwriter requesting acceleration of effectiveness for a Registration Statement on Form S-1. It is a correspondence related to a securities offering, not a financial report or detailed filing. The document is short (977 characters) and serves as a regulatory communication rather than a report or announcement of financial results. It does not contain financial data, management discussion, or audit information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2020-10-26 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Securities and Exchange Commission requesting acceleration of the effective date of a Registration Statement on Form S-1. It is a formal communication related to the registration process for securities, not a financial report or detailed filing. The document is short (1532 characters) and serves as a regulatory communication rather than a report or announcement of financial results. It does not contain financial data, audit information, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2020-10-26 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC, dated October 26, 2020. It is a registration statement under the Securities Act of 1933 for a public offering of securities (units consisting of common stock and warrants). The text includes detailed information about the offering, underwriting, risk factors, and legal matters typical of a registration statement prospectus. This is not a financial report, earnings release, or management discussion, but a capital raising filing. The Form S-1 and its amendments are filings related to capital/financing activities, specifically registration for an offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full text of the registration statement amendment, not just an announcement or notice, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2020-10-26 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes Titan Pharmaceuticals entering into a material definitive agreement related to debt settlement and release, including details of the agreement and related financial obligations. It also references exhibits attached to the filing. The document does not contain comprehensive financial statements or detailed financial performance data typical of Annual or Interim Reports. It is not a transcript, proxy, or governance document. The primary purpose is to disclose a significant financing-related event (debt settlement). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4631 characters, which is consistent with a typical 8-K filing for such an event.
2020-10-26 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically a PRE 14A preliminary proxy statement. It is related to a special meeting of stockholders to approve a reverse stock split. The text includes detailed information about the meeting, voting procedures, the purpose of the reverse split, and Nasdaq listing compliance issues. It is not a full annual report, earnings release, or financial statement, but rather a solicitation of proxies for a shareholder vote. The document is clearly a proxy statement as defined under SEC rules, used to inform shareholders and solicit their votes on corporate actions. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2020-10-23 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.